If a supplied lot fails agreed specifications, we’ll replace it at no cost or refund its purchase price in full.
Quality test failed? Free replacement or full refund.
Off-spec? Free replacement or full refund.
PCAC will review 7 peptides for the 503A bulks list, BPC-157, KPV, TB-500, MOTS-c, Emideltide, Semax, Epithalon. Read our briefing →
PCAC will review 7 peptides for the 503A bulks list. Read →
FDA PCAC reviews 7 peptides in July. Read →
Thymosin β4 fragment
Supply and ordering
Ask sales about TB-500 availability, order quantities, packaging, and batch documentation. Include other catalog items in the same inquiry if you are planning a combined or recurring order.
Overview
TB-500 is a 43-amino-acid synthetic peptide derived from Thymosin β4 (the actin-sequestering protein expressed natively in nearly every mammalian cell type). The molecule's biological activity centers on actin-binding via its central LKKTETQ motif and downstream effects on cellular migration, angiogenesis, and tissue regeneration, the mechanistic basis for the broad TB-500 research literature on wound healing, cardiac remodeling, and tendon-ligament repair models. TB-500's longer sequence relative to BPC-157 makes it serum-stable but not orally bioavailable, so research workflows are exclusively injectable-route. TB-500 is on the July 2026 FDA PCAC agenda for 503A bulks-list consideration with the proposed indication of wound healing. PeptideXpo supplies TB-500 acetate as a lyophilized powder at ≥99.0% HPLC purity. The 43-residue sequence is at the upper-middle range for routine SPPS, synthesis is reliable but purification cycles are more demanding than for shorter peptides like BPC-157, and the analytical packet emphasizes peak-integration HPLC plus mass spec to clear deletion sequences that elute close to the target peak. Sequence verification by LC-MS/MS is available on request and is the recommended qualification test for any TB-500 supplier, for a 43-mer, mass alone leaves more identity ambiguity than for a 15-mer like BPC-157. TB-500 is most commonly ordered as the standalone vial or as the Wolverine Blend with BPC-157 (5+5 mg per 10 mg vial standard, custom ratios via OEM). For the full BPC-157 vs TB-500 mechanism and analytical comparison, see our side-by-side article; for the 503A regulatory context, see our 503A vs 503B compounding guide.
Who buys this, and why
Repair peptides, BPC-157, TB-500, and related sequences, typically ship to research labs studying tissue-repair, gastrointestinal, or tendon-ligament models. Ask sales for the COA matched to the offered or supplied lot. If the buyer's written qualification procedure requires tandem-MS sequence evidence, include it in the agreed scope before quotation rather than treating it as an automatic first-batch retest.
Primary buyer fit: 503A / 503B compounding pharmacies and academic and contract research laboratories.
Specifications
Documentation available on request
A product- and strength-matched first-page preview is available below. Contact sales with the report number for the complete, high-resolution file.
Third-party testing in Tianjin
Independent HPLC and mass-spectrometry reports from Qorix, the professional, authoritative third-party analytical laboratory at tjqxgd.com, affiliated with the Tianjin International Joint Academy of Biomedicine.
Regulatory note
Currently under FDA PCAC review (July 2026) for inclusion on the 503A bulks list, with the proposed indication of wound healing.
Selected literature
Frequently asked questions
TB-500 is a 43-amino-acid synthetic peptide derived from a defined region of native Thymosin β4 (which is a 44-residue protein in mammals). The synthetic TB-500 sequence includes the LKKTETQ actin-binding motif that drives the molecule's biological activity. Compared with native Thymosin β4 produced recombinantly, the synthetic TB-500 is more economically accessible at research and commercial scale and avoids the variability that comes with cell-line-expressed material. The biological activity per mass is functionally equivalent for the actin-binding and tissue-regeneration readouts that dominate the TB-500 research literature.
TB-500 is 43 amino acids, which is at the upper-middle end of routine SPPS. Longer peptides accumulate more single-residue deletion sequences during synthesis, and those deletion products elute close to the target peak on RP-HPLC, they pass the standard HPLC purity gate but are not the molecule the buyer ordered. Mass spec alone catches identity to within 0.5 Da but cannot distinguish between, say, a [Lys-deletion at position 12] and a [Lys-deletion at position 30] of equal residue mass. LC-MS/MS sequence verification with full b- and y-ion ladder coverage is the only test that directly demonstrates the synthesized sequence matches the labelled sequence, available when required by a written analytical scope for any 40+ residue peptide.
TB-500 and BPC-157 act through different molecular mechanisms, TB-500 is an actin-binding peptide affecting cellular migration and tissue remodeling, while BPC-157 acts through nitric-oxide-pathway modulation and growth-factor-receptor cross-talk. The two are commonly combined in research and compounding contexts because the mechanisms are complementary rather than redundant. The Wolverine Blend SKU bundles both peptides into a single co-lyophilized vial at a standard 5+5 mg ratio (custom ratios available); the combined vial simplifies handling and the analytical packet certifies both components in a single document.
Related peptides
15-mer
Body Protection Compound 15-mer
BPC-157 + TB-500 repair-stack blend
Thymosin β4 active-fragment preparation
